

Issued by JPAC: 02 February 2015

Implementation: To be determined by each Service

Change Notification UK National Blood Services No. 04 - 2015

Malignancy

Applies to the Whole Blood and Components Donor Selection Guidelines only

Obligatory **Must not donate.**

Discretionary

a) If this was a non metastasized basal cell carcinoma (rodent ulcer) and local treatment is completed, all wounds are healed, and any systemic medical treatment has been completed at least 24 months previously, accept.

b) If the potential donor has a non haematological (non-clonal) premalignant condition (e.g. polyposis coli or Barrett's oesophagus) that is being regularly monitored, or has had a similar condition cured and has been discharged from follow-up, accept.

c) If the potential donor has a carcinoma in situ (e.g. cervical or vulval carcinoma in situ, ductal carcinoma in situ of the breast DCIS, prostatic intraepithelial neoplasia PIN or Bowen's disease) that has been cured and has been discharged from follow-up, accept.

d) If the potential donor has had lentigo maligna refer to clinical support to ensure that they have not had lentigo maligna melanoma.

e) Potential donors with a high risk of cancer due to family history or following genetic tests, even if had or having prophylactic surgery or on prophylactic medication (e.g. Tamoxifen), accept.

See if Relevant [Haematological Disease](#)
[Surgery](#)

Additional Information

Many malignancies spread through the blood stream and by invading surrounding tissues. Viruses that can be spread by blood and tissue donation can also cause some malignancies. For these reasons it is considered safer not to accept blood from people who have had a malignancy. However, because basal cell carcinoma (rodent ulcer) and other Carcinomas in situ do not spread through the blood,


\Continued

people who have had successful treatment may donate. Cervical carcinoma in situ would be defined as cured if treatment is complete and a follow up smear did not show abnormal cells. Regular screening smears are not defined as follow up.

Premalignant conditions are very common, particularly in older donors. Regular monitoring should prevent donors with invasive malignancy from being accepted. Clonal blood disorders are dealt with differently - see [Haematological Disease](#).

Lentigo Maligna is a common skin condition of the elderly and should be considered a carcinoma in situ and the donor may be accepted once it has been cured. However Lentigo Maligna melanoma is a true malignant melanoma and the donor must be permanently deferred if they have had this condition.

Reason for change Advice has been added for basal cell carcinoma treated systemically



Dr Sheila MacLennan
Professional Director - Joint UKBTS Professional Advisory Committee
Direct Dial: (0113) 820 8638 ✉ sheila.maclennan@nhsbt.nhs.uk